REVIEW PAPER
The role of Borrelia burgdorferi infection in scleroderma
More details
Hide details
Submission date: 2014-05-30
Final revision date: 2014-07-30
Acceptance date: 2014-10-01
Online publication date: 2014-11-17
Publication date: 2014-10-31
Reumatologia 2014;52(5):326-331
KEYWORDS
TOPICS
ABSTRACT
Borrelia burgdorferi, a Gram-negative, spiral-shaped bacterium transmitted to humans via tick bites, is the etiologic agent of borreliosis (Lyme disease) with diverse clinical manifestations. There are several types of pathological lesions in the course of Lyme disease: inflammatory, atrophic and sclerotic ones. Recent studies suggest a possible association between localized scleroderma, lichen sclerosus and Borrelia burgdorferi. A clinical similarity between late skin manifestation acrodermatitis chronica atrophicans, lichen sclerosis and morphea was noted. Studies showing regression of skin lesions in patients with localized scleroderma treated with targeted antibiotic therapy against Borrelia provide evidence for the role of the infection in the pathogenesis of morphea. The role of Borrelia burgdorferi infection in the complex pathogenesis of systemic scleroderma is still controversial. This article discusses the results of studies involving Borrelia infection in the pathogenesis of scleroderma and some dermatological disorders and describes various skin changes of borreliosis.
REFERENCES (26)
1.
Parada-Turska J. Stawowa postać boreliozy – obraz kliniczny i leczenie. Reumatologia 2013; 51: 51-55. .
2.
Breier FH, Aberer E, Stanek G, et al. Isolation of Borrelia afzelii from circumscribed scleroderma. Br J Dermatol 1999; 140: 925-930. .
3.
Barbour AG, Burgdorfer W, Grunwaldt E, Steere AC. Antibodies of patients with Lyme disease to components of the Ixodes dammini spirochete. J Clin Invest 1983; 72: 504-515. .
4.
Steere AC. Lyme disease. N Engl J Med 1989; 321: 586-596. .
5.
Berndtson K. Review of evidence for immune evasion and persistent infection in Lyme disease. Int J Gen Med 2013; 6: 291-306. .
6.
Moniuszko A, Penza P, Czupryna P, et al. The role of dendritic cells in the pathogenesis of Lyme disease. Centr Eur J Immunol 2013; 38: 569-577. .
7.
Flisiak R, Pancewicz S. Diagnostyka i leczenie boreliozy z Lyme – rekomendacje Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych. Przegl Epidemiol 2008; 62: 193-199. .
8.
Ozkan S, Atabey N, Fetil E, et al. Evidence for Borrelia burgdorferi in morphea and lichen sclerosus. Int J Dermatol 2000; 39: 278-283. .
9.
Dańczak-Pazdrowska A, Kowalczyk MJ, Szramka-Pawlak B, et al. Interleukin 1 in morphea. Centr Eur J Immunol 2012; 37: 247-252. .
10.
Dańczak-Pazdrowska A, Kowalczyk M, Szramka-Pawlak B, et al. Interleukin-17A and interleukin-23 in morphea. Arch Med Sci 2012; 8: 1089-1095. .
11.
Aberer E, Klade H, Hobisch G. A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. Am J Dermatopathol 1991; 13: 334-341. .
12.
Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol 2000; 142: 636-644. .
13.
Trevisan G, Rees DH, Stinco G. Borrelia-burgdorferi and localized scleroderma. Clin Dermatol 1994; 12: 475-479. .
14.
Fujiwara H, Fujiwara K, Hashimoto K, et al. Detection of Borrelia burgdorferi DNA (B garinii, or B afzelii) in morphea and lichen sclerosus et atrophicus tissues of German and Japanese but not of US patients. Arch Dermatol 1997; 133: 41-44. .
15.
Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? Br J Dermatol 2007; 157: 1189-1198. .
16.
Wienecke R, Schlüpen EM, Zöchling N, et al. No evidence for Borrelia burgdorferi-specific DNA in lesions of localized scleroderma. J Invest Dermatol 1995; 104: 23-26. .
17.
Liang FT, Aberer E, Cinco M, et al. Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi sp. J Infect Dis 2000; 182: 1455-1462. .
18.
Moreno C, Kutzner H, Palmedo G, et al. Interstitial granulomatous dermatitis with histiocytic pseudorosettes: a new histopathologic pattern in cutaneous borreliosis. Detection of Borrelia burgdorferi DNA sequences by a highly sensitive PCR-ELISA. J Am Acad Dermatol 2003; 48: 376-384. .
19.
Müller KE. Damage of collagen and elastic fibres by Borrelia burgdorferi – known and new clinical and histopathological aspects. Open Neurol J 2012; 6: 179-186. .
20.
Schempp C, Bocklage H, Lange R, et al. Further evidence for Borrelia-burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J Invest Dermatol 1993; 100: 717-720. .
21.
Prinz JC, Kutasi Z, Weisenseel P, et al. “Borrelia-associated early-onset morphea”: a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases. J Am Acad Dermatol 2009; 60: 248-255. .
22.
Moniuszko A, Gińdzieńska-Sieśkiewicz E, Pancewicz SA, et al. Evaluation of skin thickness lesions in patients with Lyme disease measured by modified Rodnan total skin score. Rheumatol Int 2012; 32: 3189-3191. .
23.
Mayes MD, Whittum-Hudson JA, Oszust C, et al. Lack of evidence for bacterial infections in skin in patients with systemic sclerosis. Am J Med Sci 2009; 337: 233-235. .
24.
Wackernagel A, Bergmann AR, Aberer E. Acute exacerbation of systemic scleroderma in Borrelia burgdorferi infection. J Eur Acad Dermatol Venerol 2005; 19: 93-96. .
25.
Ferri C, Cazzato M, Giuggioli D, et al. Systemic sclerosis following human cytomegalovirus infection. Ann Rheum Dis 2002; 61: 937-938. .
26.
Zakrzewska K, Corcioli F, Carlsen KM, et al. Human parvovirus B19 (B19V) infection in systemic sclerosis patients. Intervirology 2009; 52: 279-282.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.